PuSH - Publication Server of Helmholtz Zentrum München

Ziegler-Heitbrock, L. ; Frankenberger, M. ; Heimbeck, I. ; Burggraf, D. ; Wjst, M. ; Häussinger, K.* ; Brightling, C.* ; Gupta, S.* ; Parr, D.* ; Subramanian, D.* ; Singh, D.* ; Kolsum, U.* ; Boschetto, P.* ; Potena, A.* ; Gorecka, D.* ; Nowinksi, A.* ; Barta, I.* ; Döme, B.* ; Strausz, J.* ; Greulich, T.* ; Vogelmeier, C.* ; Bals, R.* ; Hohlfeld, J.* ; Welte, T.* ; Venge, P.* ; Gut, I.* ; Boland, A.* ; Olaso, R.* ; Hager, J.* ; Hiemstra, P.* ; Rabe, K.F.* ; Unmüßig, M.* ; Müller-Quernheim, J.* ; Prasse, A.*

The EvA study: Aims and strategy.

Eur. Respir. J. 40, 823-829 (2012)
Publ. Version/Full Text Volltext DOI PMC
Closed
Open Access Green as soon as Postprint is submitted to ZB.
The EvA study is an EU funded project (# 200506) under Frame Work Program 7 (FP7), which aims at defining new markers for COPD and its subtypes. The acronym is derived from emphysema versus airway disease, indicating that the project targets these two main phenotypes of the disease. The EvA study is based on the concept that emphysema and airway disease are governed by different pathophysiological processes and these are driven by different genes and a differential gene expression in the lung. To define these genes patients and non-COPD controls are recruited for clinical examination, lung function analysis and computed tomography of the lung. CT scans are used to define the phenotypes based on lung density and airway wall thickness. This is followed by bronchoscopy in order to obtain samples from the airways and the alveoli. These tissue samples along with blood samples are then subjected to genome-wide expression and association analysis and markers linked to the phenotypes are identified. The population of the EvA study is different from other COPD study populations, since patients with current oral glucocorticoid, antibiotics, exacerbations or current smoking are excluded, such that the signals detected in the molecular analysis are due to the distinct inflammatory process of emphysema and airway disease in COPD.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
5.895
2.270
9
23
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords no keywords
Language
Publication Year 2012
HGF-reported in Year 2012
ISSN (print) / ISBN 0903-1936
e-ISSN 1399-3003
Quellenangaben Volume: 40, Issue: 4, Pages: 823-829 Article Number: , Supplement: ,
Publisher European Respiratory Society
Publishing Place Sheffield
Reviewing status Peer reviewed
POF-Topic(s) 30503 - Chronic Diseases of the Lung and Allergies
30202 - Environmental Health
Research field(s) Lung Research
PSP Element(s) G-501690-001
G-501600-012
G-505000-003
PubMed ID 22441733
Scopus ID 84867122301
Erfassungsdatum 2012-04-12